FDA Law Blog

NOVEMBER 1, 2023

FDA recognizes that the FD&C Act exempts licensed healthcare practitioners from certain device regulations if they manufacture devices solely for use in the course of their professional practice. For example, FDA’s regulations have exempted from certain regulatory requirements (e.g.,

In-Vitro 81

In-Vitro Regulation Manufacturing Licensing 81

Druggist

OCTOBER 30, 2020

When taken in combination with NSAIDs such as ibuprofen, paracetamol has shown to be more effective in pain reduction than combination product containing codeine (Teoh, 2020). In fact, one branded combination products, which contain paracetamol and ibuprofen, is available in the UK.

Containment 64

Containment Pharmacy Production Branding 64

The Pharma Data

DECEMBER 28, 2020

This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Containment 52

Containment Drug Delivery Compliance Marketing 52

Pharma in Brief

APRIL 13, 2021

The Food and Drug Regulations ( FDR ) have been amended to allow for continued expedited review of COVID-19 drugs (including vaccines) while transitioning to authorizations by way of a full notice of compliance ( NOC ) under the FDR. Health Canada has also published a guidance document that contains additional information for drug sponsors.

Regulation 52

Regulation Drugs Vaccine Vaccination 52

The Pharma Data

DECEMBER 23, 2020

The Company advises that it is not making any express or implied claims that Ifenprodil has the ability to eliminate, cure or contain COVID-19 (or the SARS-2 Coronavirus) at this time. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. About NP-120 (Ifenprodil).

Containment 52

Containment Regulation Development Compliance 52

FDA Law Blog

JULY 18, 2023

Those include biological products licensed under Biologics License Applications (BLAs), approved drugs under New Drug Applications (NDAs), and generic products under approved Abbreviated New Drug Applications (ANDAs). That leaves 60% that manufacture at least one application product. The PHE also had a dramatic effect on import alerts.

Manufacturing 52

Manufacturing Production Contamination Drugs 52

The Pharma Data

MAY 14, 2021

Neither ClickBank nor the author are engaged in rendering medical or similar professional services or advice via this website or in the product, and the information provided is not intended to replace medical advice offered by a physician or other licensed healthcare provider.

Production 52

Production Sales Compliance Regulation 52

FDA Law Blog

SEPTEMBER 7, 2022

The remaining 61% of the sites manufacture at least one application product, meaning either a product resulting from a Biologics License Application (BLA), a New Drug Application (NDA), or an Abbreviated New Drug Application (ANDA).

Manufacturing 59

Manufacturing Production Containment Drugs 59

Cloudbyz

JUNE 1, 2023

Compliance: Salesforce’s data centers comply with a number of industry standards, including ISO 27001, SOC 2, and PCI DSS. Comprehensive Compliance Salesforce offers a comprehensive suite of compliance features to ensure data privacy, security, and adherence to various industry regulations. government data).

Compliance 97

Compliance Development Branding Production 97

The Pharma Data

JANUARY 18, 2021

This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Containment 40

Containment Production Drug Delivery Regulation 40

The Pharma Data

JANUARY 27, 2021

This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

In-Vitro 52

In-Vitro Containment Drugs Production 52

The Pharma Data

DECEMBER 20, 2020

This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Drug Delivery 52

Drug Delivery Containment Production Development 52

Pharma in Brief

JANUARY 10, 2021

s ( Allergan ) silodosin capsules (marketed as RAPAFLO ® ) under an exclusive license in Canada granted by Kissei Pharmaceutical Co., The Court’s decision concerns Canadian Patent No. 2,507,002 ( 002 Patent ), which is listed on the patent register against Allergan Inc.’s Allergan brought an action against Sandoz Canada Inc.

Manufacturing 52

Manufacturing Regulation Compliance Containment 52

Delveinsight

JANUARY 5, 2021

The US FDA has accepted the initial Biologics License Application submission for the therapy with the target action date for an FDA decision is October 2021. FDA Emergency Use Authorization for SCONE Medical’s Novel Aerosol Infection Containment Device. SCONE Medical Solutions Inc.

Hormones 52

Hormones FDA Approval Drugs Trials 52

Pharmacy Checkers

FEBRUARY 28, 2020

The report is an audit of companies in the drug supply chain to test compliance with regulations called for by the Drug Supply Chain Security Act of 2013 (DSCSA). The report appears to be a worthwhile effort to test compliance with DSCSA. Yesterday, I was asked by Ed Silverman of STAT NEWS’ Pharmalot. The answer is probably no.

Pharmacy 55

Pharmacy Drugs Medicine Sales 55

The Pharma Data

DECEMBER 14, 2020

This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Drug Delivery 40

Drug Delivery Containment Manufacturing Drugs 40

WCG Clinical

DECEMBER 13, 2023

In this paper, we will examine what sponsors/investigators need to consider when designing a study with dietary supplements to ensure compliance with the FDA requirements. If the objectives of the study contain a health claim the substance being studied will be considered a drug and the FDA likely will require an IND. October 17, 2023.

Regulation 40

Regulation Research Production Compliance 40

The Pharma Data

JULY 21, 2021

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. The information contained in this release is as of July 21, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

Vaccine 52

Vaccine Vaccination Manufacturing Clinical Trials 52

FDA Law Blog

MAY 20, 2021

Investigators are known to focus on areas of prior non-compliance for close scrutiny during the current inspection to ensure the registrant has remedied past deficiencies. In our experience, investigators review copies of the registrant’s federal and state licenses. They ask for the results of any state inspections.

Regulation 40

Regulation Compliance Containment Drugs 40

FDA Law Blog

MAY 20, 2021

Investigators are known to focus on areas of prior non-compliance for close scrutiny during the current inspection to ensure the registrant has remedied past deficiencies. In our experience, investigators review copies of the registrant’s federal and state licenses. They ask for the results of any state inspections.

Regulation 40

Regulation Compliance Containment Drugs 40

The Pharma Data

DECEMBER 12, 2020

Investors and security holders of Alexion are urged to carefully read the entire registration statement and proxy statement/prospectus or proxy statement and other relevant documents filed with the SEC when they become available because they will contain important information. Morgan Stanley & Co. Morgan Cazenove) (“J.P.

Development 75

Development Regulation Medicine Containment 75

The Pharma Data

OCTOBER 18, 2020

This press release contains forward-looking statements of AVEO within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements.

Sales 40

Sales Clinical Trials Clinical Trials Containment 40

FDA Law Blog

FEBRUARY 29, 2024

From there, the PTO notes that a PTE “determination is made based on the representations contained in the PTE application,” and that “35 U.S.C. § 156 or case law that would support extension of the ‘929 patent that claims the product despite revocation of the biologics license application.

Production 59

Production Drugs FDA Approval Compliance 59

The Pharma Data

JULY 27, 2021

Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. government, we could become subject to significant sanctions.

Production 52

Production Antibody Sales Development 52

The Pharma Data

SEPTEMBER 16, 2020

Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. government, we could become subject to significant sanctions.

Production 52

Production Sales Clinical Trials Clinical Trials 52

The Pharma Data

SEPTEMBER 20, 2020

About KRAS The RAS gene family, which has been the subject of almost four decades of research, contains some of the most frequently mutated oncogenes in human cancers. Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen.

Medicine 52

Medicine Production Sales Clinical Trials 52

The Pharma Data

NOVEMBER 15, 2020

a publicly traded biopharmaceutical company, from 2012 to December 2019, managing its international, legal, quality, intellectual property and compliance functions, after serving in other executive roles at Acorda starting in 2004. Before joining Acorda, Ms. More information is available at www.athersys.com. Forward-Looking Statements.

Clinical Trials 40

Clinical Trials Clinical Trials Production Trials 40

The Pharma Data

NOVEMBER 5, 2020

Collegium will grant Teva a license to market its generic version of Xtampza ER in the United States beginning on or after September 2, 2033 (subject to U.S. This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. FDA approval, and customary exceptions).

Production 52

Production Marketing Sales Manufacturing 52

The Pharma Data

NOVEMBER 9, 2020

Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures.

Trials 52

Trials Production Sales Manufacturing 52

The Pharma Data

MAY 15, 2021

The Website may contain links to other websites and banner ads that take a visitor to another Website. We may also use such information to fulfill prizes, track compliance with the applicable sweepstakes or promotion rules, or for content improvement and feedback purposes. This Website may contain certain historical information.

Production 52

Production Containment Medicine Vaccine 52

The Pharma Data

JANUARY 9, 2021

Pipeline progress is expected across the vaccines, therapeutics, and devices portfolios, anticipating at least one Phase 3 launch and one Biologics License Application (BLA)/Emergency Use Authorization (EUA) filing. FOOTNOTES. (1)

Production 40

Production Manufacturing Vaccine Vaccination 40

The Pharma Data

DECEMBER 21, 2020

Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures.

Trials 40

Trials Production Sales Manufacturing 40

The Pharma Data

OCTOBER 29, 2020

Treatment compliance rates across all our medicines have remained strong and continue to be slightly above expectations. ALXN2060 (AG10) – Eidos: Alexion holds an exclusive license to develop and commercialize ALXN2060 (AG10) in Japan. Eidos is currently evaluating AG10 in a Phase 3 study in the U.S. Forward-Looking Statement.

Sales 40

Sales Clinical Trials Clinical Trials Production 40

The Pharma Data

AUGUST 3, 2021

The company announced donanemab received Breakthrough Therapy designation for treatment of Alzheimer’s disease and its intention to submit a biologics license application (BLA) for donanemab under the accelerated approval pathway later this year based on data from TRAILBLAZER-ALZ. Numbers may not add due to rounding.

Antibody 52

Antibody Sales Development Production 52

The Pharma Data

APRIL 27, 2021

reflecting lower treatment compliance during the COVID-19 pandemic. On January 12, 2021 Sanofi entered into a global licensing agreement with Biond Biologics for BND-22, a novel immune checkpoint inhibitor targeting the ILT2 receptor. First-quarter Fabrazyme ® sales increased 4.7% In the U.S. sales decreased 2.9% Net sales (€ million).

Sales 52

Sales Vaccine Vaccination Medicine 52

FDA Law Blog

JANUARY 8, 2023

Also of great importance is the Act’s authorizing state-licensed physicians to advise patients or their legal guardians of the potential harms and benefits of cannabis derivatives as a medical treatment. Is licensed by each state in which it will conduct operations. Doctor-Patient Relationship. 21 U.S.C. §

Research 64

Research Manufacturing Regulation Licensing 64

The Pharma Data

AUGUST 6, 2020

announced that the companies submitted the Biologics License Application (BLA) to the U.S. The information contained on, or that may be accessed through, our website or social media channels are not incorporated by reference into, and are not a part of, this document. In June, the company and Acceleron Pharma Inc. Regulatory.

Production 52

Production Branding Marketing Containment 52